Dravet Syndrome

Neurology·MeSH: Epilepsies, Myoclonic

Prevalence

5.0 / 100K

19 drugs in development·13 companies·15 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
capvaxive	Ligand Pharmaceuticals Incorporated (LGND)

Phase 3(12)

Drug	Company
Clemizole HCl	Harmony Biosciences Holdings, Inc. (HRMY)
EPX-100	Harmony Biosciences Holdings, Inc. (HRMY)
fenfluramine	IDEAYA Biosciences, Inc. (IDYA)
gene therapies for dravet syndrome	ZOGENIX, INC. (ZGNX)
LP352	Longboard Pharmaceuticals, Inc. (LBPH)
Relutrigine	Praxis Precision Medicines, Inc. (PRAX)
soticlestat	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
soticlestat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
soticlestat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
zorevunersen	Stoke Therapeutics, Inc. (STOK)
Zorevunersen	BIOGEN INC. (BIIB)
zx008	ZOGENIX, INC. (ZGNX)

Preclinical(3)

Drug	Company
nav1.1 lead candidate	Xenon Pharmaceuticals Inc. (XENE)
nav1.1 program	Xenon Pharmaceuticals Inc. (XENE)
nobrxiol	Virpax Pharmaceuticals, Inc. (VRPX)

Phase 1/Phase 2(3)

Drug	Company
ion337	IONIS PHARMACEUTICALS INC (IONS)
stk-001 - multiple ascending doses	Stoke Therapeutics, Inc. (STOK)
stk-001 - single ascending doses	Stoke Therapeutics, Inc. (STOK)

BioSniper tracks 19 drugs in development for Dravet Syndrome across 13 companies.

There are 15 clinical trials targeting Dravet Syndrome tracked by BioSniper.

The estimated prevalence of Dravet Syndrome is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.